Cargando…

Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis

IMPORTANCE: HIV preexposure prophylaxis (PrEP) is a key component of the Ending the HIV Epidemic (EHE) Initiative to curb new HIV diagnoses. In October 2019, emtricitabine/tenofovir alafenamide was added as an approved formulation for PrEP in addition to emtricitabine/tenofovir disoproxil fumarate;...

Descripción completa

Detalles Bibliográficos
Autores principales:	McManus, Kathleen A., Fuller, Benjamin, Killelea, Amy, Strumpf, Andrew, Powers, Samuel D., Rogawski McQuade, Elizabeth T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638648/ https://www.ncbi.nlm.nih.gov/pubmed/37948076 http://dx.doi.org/10.1001/jamanetworkopen.2023.42781

Ejemplares similares

Regional Disparities in Qualified Health Plans’ Prior Authorization Requirements for HIV Pre-exposure Prophylaxis in the United States
por: McManus, Kathleen A., et al.
Publicado: (2020)

Worsening Disparities in State-Level Uptake of Human Immunodeficiency Virus Preexposure Prophylaxis, 2014–2018
por: Powers, Samuel D, et al.
Publicado: (2021)

Inequities in the Geographic Accessibility of COVID-19 Biomedical Therapeutic Trials in the United States
por: Khazanchi, Rohan, et al.
Publicado: (2021)

870. Coverage, Cost Sharing, and Out-of-Pocket Costs for Single-Tablet HIV Antiretroviral Regimens in Qualified Health Plans in the United States, 2018-2020
por: Khazanchi, Rohan, et al.
Publicado: (2021)

Medicaid Expansion’s Impact on Human Immunodeficiency Virus Outcomes in a Nonurban Southeastern Ryan White HIV/AIDS Program Clinic
por: McManus, Kathleen A, et al.
Publicado: (2020)

1030. Medicaid Expansion: How Does it Impact HIV Outcomes in One Non-urban Southeastern Ryan White HIV/AIDS Program Clinic?
por: McManus, Kathleen A, et al.
Publicado: (2020)

Evidence From a Multistate Cohort: Enrollment in Affordable Care Act Qualified Health Plans’ Association With Viral Suppression
por: McManus, Kathleen A, et al.
Publicado: (2019)

1545. Three Site Testing for Sexually Transmitted Infections for People Living with HIV in One Southeastern Ryan White HIV/AIDS Program Clinic: First Year of Experience
por: Geba, Maria, et al.
Publicado: (2020)

883. Evidence from a Multistate Cohort: Enrollment in Affordable Care Act Qualified Health Plans Results in Viral Suppression
por: McManus, Kathleen A, et al.
Publicado: (2019)

A Missed Opportunity: Extragenital Screening for Gonorrhea and Chlamydia Sexually Transmitted Infections in People With HIV in a Southeastern Ryan White HIV/AIDS Program Clinic Setting
por: Geba, Maria C, et al.
Publicado: (2022)

Access to a novel first-line single-tablet HIV antiretroviral regimen in Affordable Care Act Marketplace plans, 2018–2020
por: Khazanchi, Rohan, et al.
Publicado: (2023)

Geographic Accessibility of COVID-19 Test to Treat Sites by Race, Ethnicity, Age, and Rurality
por: Khazanchi, Rohan, et al.
Publicado: (2022)

The European preexposure prophylaxis revolution
por: Cairns, Gus, et al.
Publicado: (2016)

Hepatitis C Within a Single Health System: Progression Along the Cascade to Cure Is Higher for Those With Substance Misuse When Linked to a Clinic With Embedded Support Services
por: Sherbuk, J E, et al.
Publicado: (2018)

Eligibility for HIV Preexposure Prophylaxis, Intention to Use Preexposure Prophylaxis, and Informal Use of Preexposure Prophylaxis Among Men Who Have Sex With Men in Amsterdam, the Netherlands
por: Hulstein, Sebastiaan H., et al.
Publicado: (2021)

Economic benefits of the United States’ AIDS drug assistance Program: A systematic review of cost analyses to guide research and policy priorities
por: McManus, Kathleen A., et al.
Publicado: (2022)

883. The Current State of Access: Inequitable Access to Infectious Disease Physicians in the Time of the COVID-19 Pandemic and Declining Fellowship Match Rates
por: Fuller, Benjamin P, et al.
Publicado: (2023)

The use of preexposure treatments for HIV prophylaxis
por: Majid, Adrian, et al.
Publicado: (2012)

Statistical issues in trials of preexposure prophylaxis
por: Dunn, David T., et al.
Publicado: (2016)

Assisters Succeed in Insurance Navigation for People Living with HIV and People at Increased Risk of HIV in a Complex Coverage Landscape
por: McManus, Kathleen A., et al.
Publicado: (2020)

Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine
por: Rogawski McQuade, Elizabeth T, et al.
Publicado: (2021)

Access to Medications for Opioid Use Disorder for Persons With Human Immunodeficiency Virus in the United States: Gaps in Coverage by State AIDS Drug Assistance Programs
por: McManus, Kathleen A, et al.
Publicado: (2022)

Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women
por: Anderson, Peter L., et al.
Publicado: (2016)

Oral preexposure prophylaxis continuation, measurement and reporting
por: Stankevitz, Kayla, et al.
Publicado: (2020)

Introducing riskCommunicator: An R package to obtain interpretable effect estimates for public health
por: Grembi, Jessica A., et al.
Publicado: (2022)

Increased HIV Transmissions With Reduced Insurance Coverage for HIV Preexposure Prophylaxis: Potential Consequences of Braidwood Management v. Becerra
por: Paltiel, A David, et al.
Publicado: (2023)

P41 - Preexposure prophylaxis of infants’ food allergy
por: Denisova, Svetlana, et al.
Publicado: (2014)

Preexposure prophylaxis strategies for African–American women affected by mass incarceration
por: Adams, Joëlla W., et al.
Publicado: (2021)

Effect of 6-Month HIV Preexposure Prophylaxis Dispensing With Interim Self-testing on Preexposure Prophylaxis Continuation at 12 Months: A Randomized Noninferiority Trial
por: Ortblad, Katrina F., et al.
Publicado: (2023)

A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis
por: Fuchs, Jonathan D., et al.
Publicado: (2018)

Ryan White HIV/AIDS Part B and AIDS Drug Assistance Programs during COVID-19: safety net public health programs’ challenges and innovations
por: McManus, Kathleen A., et al.
Publicado: (2023)

Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence
por: Amico, K. Rivet, et al.
Publicado: (2014)

Weighing the Risk of Drug Resistance With the Benefits of HIV Preexposure Prophylaxis
por: Grant, Robert M., et al.
Publicado: (2015)

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
por: Fonner, Virginia A., et al.
Publicado: (2016)

The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion
por: Donnell, Deborah, et al.
Publicado: (2017)

Preexposure Prophylaxis for the Prevention of HIV Infection — 2014 Available Online
Publicado: (2014)

Optimizing Delivery of HIV Preexposure Prophylaxis for Women in the United States
por: Aaron, Erika, et al.
Publicado: (2018)

HIV Preexposure Prophylaxis in the U.S. Military Services — 2014–2016
por: Blaylock, Jason M., et al.
Publicado: (2018)

Sharing experience: Hydroxychloroquine in preexposure prophylaxis against COVID-19
por: Kulkarni, Chanda, et al.
Publicado: (2021)

Clinical Considerations in the Selection of Preexposure Prophylaxis for HIV Prevention in Canada
por: Knox, David C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vjkggq6u5bhccaihlj7tif6hfp